The cannabinoid receptor type 2, abbreviated as CB2, is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. It is closely related to the cannabinoid receptor type 1, which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol, the active agent in marijuana,and other phytocannabinoids. The principal endogenous ligand for the CB2 receptor is 2-arachidonoylglycerol (2-AG).
CB2 was cloned in 1993 by a research group from Cambridge looking for a second cannabinoid receptor that could explain the pharmacological properties of tetrahydrocannabinol. The receptor was identified among cDNAs based on its similarity in amino-acid sequence to the cannabinoid receptor type 1 (CB1) receptor, discovered in 1990. The discovery of this receptor helped provide a molecular explanation for the established effects of cannabinoids on the immune system.
Decades of Scientific Research People smoke marijuana to relieve pain, have sleep easier and treat nausea, lack of appetite and mood disorders such as anxiety, stress and depression. Now researchers suggest that multiple sclerosis could join the growing list of … Continue reading →
